Stocks Health care CRVS
NASDAQ · Health careCorvus Pharmaceuticals, Inc. (CRVS)
It posted a net loss of $64.3M. In fiscal 2025 capital spending exceeded operating cash flow by $33M. At September 30, 2026 it held $15M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Corvus Pharmaceuticals, Inc.
- Net worth
- Corvus Pharmaceuticals, Inc. has a market value (market cap) of $954.8M at the latest share price, and shareholders' equity of $208.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $32.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Corvus Pharmaceuticals, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Corvus Pharmaceuticals, Inc. does
Corvus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$15.3M | -$0.53 | -$33M |
| 2024 | n/a | -$62.3M | -$1.02 | n/a |
| 2023 | n/a | -$27M | -$0.56 | -$24M |
| 2021 | n/a | -$41.3M | -$0.89 | -$27.3M |
| 2021 | n/a | -$43.2M | -$1.03 | -$36.7M |
| 2020 | n/a | -$6M | -$0.20 | -$34.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Corvus Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 22, 2026
- June 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Corvus Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 11, 2026 | Moore David ScottDirector | Bought | 21,700 | $250.2K |
| May 18, 2026 | Miller Richard A MdPresident and CEO, Director | Boughtindirect | 5,000 | $60.3K |
| May 18, 2026 | Miller Richard A MdPresident and CEO, Director | Boughtindirect | 1,932 | $23.2K |
| January 28, 2026 | Thompson Peter A.Director, 10% owner | Exercised options | 30,000 | $450K |
| January 28, 2026 | Thompson Peter A.Director, 10% owner | Exercised options | 15,000 | $145.5K |
| January 28, 2026 | Thompson Peter A.Director, 10% owner | Exercised options | 15,000 | $187.5K |
| January 28, 2026 | Thompson Peter A.Director, 10% owner | Exercised options | 15,000 | $54.2K |
| January 28, 2026 | Thompson Peter A.Director, 10% owner | Exercised options | 15,000 | $30K |
Who owns CRVS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbimed Advisors LLC13D, may seek influence with 1 related filers | 10.3% | January 27, 2026 |
| Richard A. Miller13G, passive with 2 related filers | 7.8% | February 13, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 7.5% | May 15, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 1,426,735 shares in total, about $16.2M at the last price.
| Holder | Shares |
|---|---|
| Miller Richard A MdPresident and CEO, Director | 1,195,0351,195,035 held indirectly |
| Thompson Peter A.Director, 10% owner | 210,000 |
| Moore David ScottDirector | 21,700 |
Questions about CRVS
What does Corvus Pharmaceuticals, Inc. do?
Corvus Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as CRVS. Its shares trade on NASDAQ under the ticker CRVS.
What is Corvus Pharmaceuticals, Inc.'s net worth?
Corvus Pharmaceuticals, Inc. has a market value (market cap) of $954.8M at the latest share price, and shareholders' equity of $208.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Corvus Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $64.3M.
When did Corvus Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Corvus Pharmaceuticals, Inc.'s next earnings report?
Corvus Pharmaceuticals, Inc.'s next report is expected around March 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CRVS with
Follow CRVS
Get an email when Corvus Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Corvus Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.